RP-HPLC METHOD WITH UV DETECTION FOR THE EVALUATION OF CHITOSAN-GRAFT-Β-CYCLODEXTRIN/PVA HYDROGELS AS CARRIERS FOR THE CONTROLLED RELEASE OF VEMURAFENIB
DOI:
https://doi.org/10.22551/902ky316Abstract
When developing a topical formulation, it is essential to evaluate it from the perspective of its carrier capacity for the controlled release of the encapsulated drug. The drug should be simply quantified through an accurate and reproducible method. This paper presents a rapid, simple, sensitive, and reproducible high-performance liquid chromatography method with UV detection for evaluating the ability of chitosan-graft-β-cyclodextrin/PVA (CS-g-β-CD/PVA) hydrogels as carriers for the controlled release of vemurafenib (VEM). Materials and methods: The chromatographic separation was achieved using a Waters CORTECS C18 column (100 × 2.1 mm ID, 2.7 µm). The mobile phase was a mixture of: A (water/formic acid - 99.9/0.1, v/v), B (acetonitrile), and C (methanol) in the ratio of 40: 55: 5 (v/v/v). The injection sample amount was 10 μL, and the run time was 9 minutes in isocratic mode at a flow rate of 1 mL/min. The analyte was detected using UV absorption at 252 nm. Results: The standard calibration curve was linear over the concentration range of 0.78-100 mg/L. The values for LOD and LOQ were 0.5 mg/L and 0.75 mg/L, respectively. The intra- and inter-day precision of measurements were lower than the accepted criteria (RSD ≤ 2%). The high value of recoveries obtained for VEM indicates that the proposed method was found to be accurate. The stability of VEM solutions was assessed, indicating that the drug remained stable under all relevant conditions. Conclusions: Finally, the validated method was successfully applied to evaluate the ability of chitosan-graft-β-cyclodextrin/PVA hydrogels to load and sustain release of VEM. The drug entrapment efficiency (DEE%) was between 65±0.08% and 70±0.05%.
References
1. Richard MA, Paul C, Nijsten T, Gisondi P, Salavastru C, Taieb C, et al. Prevalence of most common skin diseases in Europe: a population‐based study. J Eur Acad Dermatol Venereol 2022; 36(7): 1088-1096.
2. Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers (Basel) 2022; 14(19): 4652.
3. Koizumi S, Inozume T, Nakamura Y. Current surgical management for melanoma. J Dermatol 2024; 51(3): 312-323.
4. Alieva M, van Rheenen J, Broekman MLD. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin Exp Metastasis 2018; 35(4): 319-331.
5. National Cancer Institute. Melanoma Treatment (PDQ®)-Health Professional Version. National Insti-tutes of Health, 26.04.2024, https: //www.cancer.gov/types/skin/ hp/ melanoma-treatment-pdq (accessed on 1 May 2025).
6. Grynberg S, Stoff R, Asher N, et al. Radiotherapy may augment response to immuno-therapy in metastatic uveal melanoma patients. Ther Adv Med Oncol 2022; 14.
7. D’Andrea MA, Reddy GK. Systemic Antitumor Effects and Abscopal Responses in Melanoma Pa-tients Receiving Radiation Therapy. Oncology 2020; 98(4): 202-215.
8. Pham JP, Joshua AM, da Silva IP, Dummer R, Goldinger SM. Chemotherapy in Cutaneous Melano-ma: Is There Still a Role? Curr Oncol Rep 2023; 25(6): 609-621.
9. Haider T, Pandey V, Banjare N, Gupta PN, Soni V. Drug resistance in cancer: mechanisms and tack-ling strategies. Pharmacol Rep 2020; 72(5): 1125-1151.
10. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel) 2023; 15(4): 1106.
11. da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive un-resectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Me-dicinal Products for Human Use. Eur J Cancer 2013; 49(7): 1654-1661.
12. Oneal PA, Kwitkowski V, Luo L, et al. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAF V600 Mutation. Oncologist 2018; 23(12): 1520-1524.
13. Russi M, Valeri R, Marson D, et al. Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. Eur J Pharm Sci 2023; 180: 106311.
14. Kim J, Archer PA, Manspeaker MP, Avecilla ARC, Pollack BP, Thomas SN. Sustained release hy-drogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. J Control Release 2023; 357: 655-668.
15. Zou L, Ding W, Zhang Y, et al. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. Biomaterials 2018; 182: 1-12.
16. Bîrsan M, Cristofor AC, Antonoaea P, et al. Evaluation of miconazole nitrate permeability through biological membrane from dermal systems. Farmacia 2020; 68(1): 111-115.
17. Almajidi YQ, Maraie NK, Raauf AMR. Modified solid in oil nanodispersion containing vemurafenib-lipid complex-in vitro/in vivo study. F1000Res 2022; 11: 841.
18. Alkilani A, McCrudden MT, Donnelly R. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the Stratum Corneum. Pharmaceutics 2015; 7(4): 438-470.
19. Almajidi YQ, Maraie NK, Raauf AMR. Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma. Appl Nanosci (Switzerland) 2023; 13(4): 2845-2856.
20. Alex M, Alsawaftah NM, Husseini GA. State-of-All-the-Art and Prospective Hydrogel-Based Trans-dermal Drug Delivery Systems. Appl Sci 2024; 14(7): 2926.
21. Jacob S, Nair AB, Shah J, Sreeharsha N, Gupta S, Shinu P. Emerging Role of Hydrogels in Drug Delivery Systems, Tissue Engineering and Wound Management. Pharmaceutics 2021; 13(3): 357.
22. Esmaeili J, Barati A, Ai J, Nooshabadi VT, Mirzaei Z. Employing hydrogels in tissue engineering approaches to boost conventional cancer-based research and therapies. RSC Adv 2021; 11(18): 10646-10669.
23. Caccavo D, Cascone S, Lamberti G, Barba AA. Controlled Drug Release from Hydrogel-Based Ma-trices: Experiments and Modeling. Int J Pharm 2015; 486: 144-152.
24. Păduraru L, Panainte AD, Peptu CA, et al. Smart Drug Delivery Systems Based on Cyclodextrins and Chitosan for Cancer Therapy. Pharmaceuticals (Basel) 2025; 18(4): 564.
25. Chuah LH, Loo HL, Goh CF, Fu JY, Ng SF. Chitosan-based drug delivery systems for skin atopic dermatitis: recent advancements and patent trends. Drug Deliv Transl Res 2023; 13(5): 1436-1455.
26. Chander S, Piplani M, Waghule T, Singhvi G. Role of Chitosan in Transdermal Drug Delivery. In: Chitosan in Drug Delivery. Elsevier, 2022, 83-105.
27. Ketabchi N, et al. Study of Third-Degree Burn Wounds Debridement and Treatment by Actinidin Enzyme Immobilized on Electrospun Chitosan/PEO Nanofibers in Rats. Biointerface Res Appl Chem 2020; 11(3): 10358-10370.
28. Tiplea RE, Lemnaru GM, Trușcă RD, et al. Antimicrobial films based on chitosan, collagen, and zno for skin tissue regeneration. Biointerface Res Appl Chem 2021; 11(4): 11985-11995.
29. Nieto González N, Rassu G, Cossu M, et al. A thermosensitive chitosan hydrogel: An attempt for the nasal delivery of dimethyl fumarate. Int J Biol Macromol 2024; 278.
30. Naeem A, Chengqun Y, Hetonghui, Zhenzhong Z, Weifeng Z, Yongmei G. β-Cyclodextrin/chitosan-based (polyvinyl alcohol-co-acrylic acid) interpenetrating hydrogels for oral drug delivery. Int J Biol Macromol 2023; 242: 125-149.
31. Najm A, Niculescu AG, Bolocan A, et al. Chitosan and Cyclodextrins-Versatile Materials Used to Create Drug Delivery Systems for Gastrointestinal Cancers. Pharmaceutics 2023; 16(1): 43.
32. Tian B, Hua S, Liu J. Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: A review. Carbohydr Polym 2020; 232: 115805.
33. Kali G, Haddadzadegan S, Bernkop-Schnürch A. Cyclodextrins and derivatives in drug delivery: New developments, relevant clinical trials, and advanced products. Carbohydr Polym 2024; 324: 121500.
34. Choi JH, Lee JS, Yang DH, et al. Development of a Temperature-Responsive Hydrogel Incorporating PVA into NIPAAm for Controllable Drug Release in Skin Regeneration. ACS Omega 2023; 8(46): 44076-44085.
35. Manohar D, Babu RS, Vijaya B, et al. A review on exploring the potential of PVA and chitosan in biomedical applications: A focus on tissue engineering, drug delivery and biomedical sensors. Int J Biol Macromol 2024; 283: 137318.
36. Panainte AD, Popa, G, Pamfil D, et al. In Vitro Characterization of Polyvinyl Alcohol/ Chitosan Hydrogels as Modified Release Systems for Bisoprolol. Farmacia 2018; 66: 1.
37. Păduraru L, Sava A, Orhan H, et al. Vemurafenib Based Hydrogels as Potential Topical Bioformula-tions For the Treatment of Melanoma. Med Surg. J - Rev Med Chir Soc Med Nat 2025; 129: 278-290.
38. Sparidans RW, Durmus S, Schinkel AH, Schellens JHM, Beijnen JH. Liquid chromato-graphy-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. J Chromatogr B 2012; 889-890: 144-147.
39. Vakhariya RR, Shah RR, Patil SS, Salunkhe NS, Mohite SK. Development and Validation of Analyt-ical Method for Vemurafenib. Int J Curr Sci 2024; 14: 519-529.
40. Pawanjeet. JC, Balaji M, Srinivasarao V, Appa Rao KM. Development and validation of a new simple and stability indicating RP-HPLC method for the determination of vemurafenib in presence of degradant products. Der Pharma Chemica 2013; 5(5): 189-198.
41. Nijenhuis CM, Rosing H, Schellens JHM, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. J Pharm Biomed Anal 2014; 88: 630-635.
42. Ravix A, Bandiera C, Cardoso E, et al. Population Pharmacokinetics of Trametinib and Impact of Nonadherence on Drug Exposure in Oncology Patients as Part of the Optimizing Oral Targeted Anti-cancer Therapies Study. Cancers (Basel) 2024; 16(12): 2193.
43. Rousset M, Titier K, Bouchet S, et al. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. Clinica Chimica Acta 2017; 470: 8-13.
44. Zheng Y, Thomas-Schoemann A, Sakji L, et al. An HPLC-UV method for the simultaneous quantifi-cation of vemurafenib and erlotinib in plasma from cancer patients. J Chromatogr B 2013; 928: 93-97.
45. Shah N, Iyer RM, Mair HJ, et al. Improved Human Bioavailability of Vemurafenib, a Practically Insoluble Drug, Using an Amorphous Polymer-Stabilized Solid Dispersion Prepared by a Solvent-Controlled Coprecipitation Process. J Pharm Sci 2013; 102(3): 967-981.
46. Alvarez JC, Funck-Brentano E, Abe E, Etting I, Saiag P, Knapp A. A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. J Pharm Bi-omed Anal 2014; 97: 29-32.
47. U.S. Department of Health and Human Services; Food and Drug Administration (FDA); Center for Drug Evaluation and Research (CDER); Center for Veterinary Medicine (CVM). Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations, 2018.
48. Committee for Medicinal Products for Human Use ICH Q2(R2). Guideline on Validation of Analytical Procedures, 2023.
49. Panainte AD, Vieriu M, Tantaru G, Apostu M, Bibire N. Fast HPLC Method for the Determination of Piroxicam and its Application to Stability Study. Revista de Chimie 2017; 68(4): 701-706.
50. Moosavi SM and Ghassabian S. Linearity of Calibration Curves for Analytical Methods: A Review of Criteria for Assessment of Method Reliability. In: Calibration and Validation of Analytical Methods - A Sampling of Current Approaches. InTech, 2018.
51. European Pharmacopoeia, 7th edition. Chapter 4.1.3. Buffer Solutions, Council of Europe, Strasbourg, 2010, 489-494.
52. Kaufmann A, Butcher P, Maden K, Walker S, Widmer M, Kaempf R. Improved method robustness and ruggedness in liquid chromatography-mass spectrometry by increasing the acid content of the mobile phase. J Chromatogr A 2024; 1717: 464694.
53. International Conferences on Harmonization of Technical requirements for the registration of Drugs for Human use (ICH) Q2B. Validation of Analytical Procedure; Methodology, 2003.
54. Lakka SN, Kuppan C. Principles of Chromatography Method Development. In: Biochemical Analysis Tools - Methods for Bio-Molecules Studies. IntechOpen, 2020.
55. Satinder Ahuja and Michael W. Dong. Handbook of Pharmaceutical Analysis by HPLC. Academic Press, 2005, 6.
56. Almpani S, Agiannitou PI, Monou PK, Kamaris G, Markopoulou CK. Development of a Validated HPLC-UV Method for the Determination of Panthenol, Hesperidin, Rutin, and Allantoin in Pharma-ceutical Gel-Permeability Study. Separations 2025; 12(2): 19.
57. Nilima S, Pragati Ranjan S, Madhu Chhanda M, Bisakha T. Bhavna, G. A New Analytical Rp-Hplc Method for The Estimation of Vemurafenib In Pure Form and Marketed Pharmaceutical Dosage Form. Der Pharma Chemica 2023.
58. Gioacchino Luca Losacco; Amandine Dispas; Jean-Luc Veuthey and Davy Guillarme. Application Space for SFC in Pharmaceutical Drug Discovery and Development. In: Practical Application of Su-percritical Fluid Chromatography for Pharmaceutical Research and Development 2022; 14: 29-47.
59. Neamah MJ, Al-Akkam EJM. Preparation and characterization of vemurafenib microemulsion based hydrogel using surface active ionic liquid. Pharmacia 2024; 71: 1-9.
60. Shi H, Zhang X, Gao Y, Wang S, Ning Y. Robust Total Least Squares Estimation Method for Uncer-tain Linear Regression Model. Mathematics 2023; 11(20): 4354.
61. Güven, G. Development and Validation of a RP-HPLC Method for Vemurafenib in Human Urine. Lat Am J Pharm 2019; 38 (4): 1-5.
62. Anusha D, Yasodha A and Venkatesh M.-V. A New Analytical RP-HPLC Method for the Estimation of Vemurafenib in Pure Form and Marketed Pharmaceutical Dosage Form. Tijer-International Re-search Journal 2023, 10.
63. The United States Pharmacopeial Convention. USP34 - NF29, Volume 1. Rockville, Maryland, 2011.
64. Bibire T, Panainte AD, Yilmaz CN, et al. Dexketoprofen-Loaded Alginate-Grafted Poly(N-vinylcaprolactam)-Based Hydrogel for Wound Healing. Int J Mol Sci 2025; 26(7): 3051.
65. Peppas NA, Narasimhan B. Mathematical models in drug delivery: How modeling has shaped the way we design new drug delivery systems. J Control Release 2014; 190: 75-81.
66. Grassi M, Grassi G. Application of mathematical modeling in sustained release delivery systems. Expert Opin Drug Deliv 2014; 11(8): 1299-1321.
67. Jackson N, Ortiz AC, Jerez A, Morales J, Arriagada F. Kinetics and Mechanism of Camptothecin Release from Transferrin-Gated Mesoporous Silica Nanoparticles through a pH-Responsive Surface Linker. Pharmaceutics 2023; 15(6): 1590.
68. Ata S, Rasool A, Islam A, et al. Loading of Cefixime to pH sensitive chitosan-based hydrogel and investigation of controlled release kinetics. Int J Biol Macromol 2020; 155: 1236-1244.
69. Raina N, Pahwa R, Bhattacharya J, et al. Drug Delivery Strategies and Biomedical Significance of Hydrogels: Translational Considerations. Pharmaceutics 2022; 14(3): 574.
Additional Files
Published
Issue
Section
License
Copyright (c) 2025 The Medical-Surgical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
